Clinical Trial: A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07091630) titled 'A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP' on July 22.

Brief Summary: The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months).

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: Chronic Inflammatory Demyelinating Polyneuropathy CIDP Chronic Inflammatory Demyelinating Polyradiculo...